[Optimal conditions for producing immunomodulating effect of epithalamine as component of neoadjuvant chemotherapy using autoplasma and autoblood in patients with locally advanced breast cancer].
Neoadjuvant chemotherapy was given to 105 patients with locally advanced breast cancer after incubation of cytostatics with autoplasma (APCT) and autoblood (AHCT). Most of them also received epithalamine after incubation with AHCT. That significantly improved such parameters of cellular immunity as T-cell content, their subset distribution and function. The most favorable changes were observed when epithalamine was used in conjunction with AHCT. A similar immuno-modulating effect was exerted when epithalamine was used irrespective of either CMAV or CMFV regimens.
E Iu
EIu
Zlamnik
L Iu
LIu
Vladimirova
G I
GI
Zakora
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D010455:Peptides; C027437:epithalamin